Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA.
Leuk Lymphoma. 2024 Jan;65(1):48-54. doi: 10.1080/10428194.2023.2270766. Epub 2024 Jan 10.
Individual reports described lymphoproliferative disorders (LPDs) after COVID-19 vaccination; however, the relationship between cases is unexamined. We aim to determine if there are cases of cutaneous LPDs associated with COVID-19 vaccination and their outcomes. We present a review of world literature, vaccine registries, and two unreported cases of LPDs after COVID-19 vaccination. Review of the medical literature, VAERS, and our two cases reveal predominance of Pfizer-BioNTech vaccine, younger patients, and males. All cases resulted in favorable outcomes. Approximately 84% of cases demonstrated CD30+ positivity in their skin biopsies, suggesting that an antigenic trigger may lead to a type IV adaptive immune response, with clonal expansion of CD30+ T-cells and subsequent oncogenic mutational hits eventuating in transient LPDs. LPDs after COVID-19 vaccination appear in the context of the same vaccines (proportionally to their global market shares), share clinical and pathological findings, and have indolent, self-limited character.
有个别报告描述了 COVID-19 疫苗接种后发生的淋巴增生性疾病（LPD）；然而，这些病例之间的关系尚未得到研究。我们旨在确定是否存在与 COVID-19 疫苗接种相关的皮肤 LPD 病例及其结局。我们回顾了世界文献、疫苗登记处以及两例 COVID-19 疫苗接种后未报告的 LPD 病例。对医学文献、VAERS 和我们的两例病例的回顾显示，辉瑞-生物技术疫苗更为常见，患者更年轻，且为男性。所有病例的结局均良好。大约 84%的病例在皮肤活检中表现出 CD30+阳性，这表明抗原触发可能导致 IV 型适应性免疫反应，CD30+T 细胞的克隆扩增，随后发生致癌性突变，导致短暂的 LPD。COVID-19 疫苗接种后的 LPD 出现在相同的疫苗中（与它们的全球市场份额成比例），具有相似的临床和病理表现，且具有惰性、自限性特征。
